Floatz logo

cd22 car-t

Hairy Cell Leukemia

Stanford UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Hairy Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Kite, A Gilead Company
Phase 2BB
Cediranib
Alexey Danilov, MD
Phase 1/2B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Acerta Pharma BV
Phase 1/2B
Fludarabine
Kite, A Gilead Company
Phase 2B
Obinutuzumab
Joseph Tuscano
Phase 1/2B

View all 41 →

Same molecule, other indications

cd22 car-t is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell Lymphoma RecurrentDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →